Navigation Links
Symmetry Medical Reports Full Year 2007 Financial Results
Date:4/23/2008

to restated full year 2006 gross margin of 23.0%. Full year 2007 gross margin was negatively impacted by operational issues and other expenses at the Company's Sheffield UK facility, including extreme flooding in Sheffield and the surrounding areas in June of 2007, a lower percentage of large projects in the Company's core business and increased fixed costs associated with capacity expansion in prior years.

Selling, general and administrative expenses were $39.5 million for the total year 2007, compared with restated full year 2006 of $28.3 million. The year-over-year increase was primarily driven by the inclusion of $6.5 million of expense from the acquisitions and $3.5 million in professional fees and expenses incurred in connection with the review of accounting irregularities at the Sheffield, UK operating unit and related restatements.

The Company's effective tax rate in fiscal 2007 was significantly impacted by a valuation allowance on the net operating loss carry-forward at our Sheffield, UK operating unit of $1.8 million and a $1.4 million reserve for prior year tax positions.

Net loss for total year 2007 was $0.1 million, or $(0.00) per diluted share, compared to restated full year 2006 net income of $18.5 million, or $0.53 per diluted share.

The Company had total cash and cash equivalents of $12.1 million at December 31, 2007, compared to $11.7 million at December 31, 2006.

Brian Moore, President and Chief Executive Officer, stated, "Our restated financial statements represent the completion of a significant undertaking. While I am pleased that the restatements were solely restricted to the Sheffield, UK operating unit, the accounting review and investigation has been a long and arduous task. We have come out of the process a stronger company, with new management in Europe as well as enhanced controls. Throughout all of this, we worked hard to maintain our excellent customer service and continued to deliver quality product
'/>"/>

SOURCE Symmetry Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
2. Symmetry Medical Launches New Global Web site
3. Symmetry Medical Appoints John Hynes Chief Operating Officer, Europe
4. Symmetry Medical Provides Update of Previously Disclosed Accounting Review at Sheffield, UK Operating Unit
5. Symmetry Medical Completes Acquisition of DePuy Orthopaedic Instrument Facility
6. Symmetry Medical to Provide Fourth Quarter 2007 General Business Update on February 14, 2008
7. Facial asymmetry persists despite surgery to correct congenital deformity
8. Symmetry Medical to Expand Malaysian Operations
9. Symmetry Medical Delays 10-K Filing to Complete Review
10. MSU engineering team designs innovative medical device
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 2Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 3Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 4Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 2Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 3Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 4Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 5Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 6Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 2Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 3Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 4Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 5Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 6Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 7Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 8Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 9Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis 10Over 74 000 Participate in President Obama Teleforum on Healthcare Reform 53015 1Over 74 000 Participate in President Obama Teleforum on Healthcare Reform 53015 2Caraco Pharmaceutical Laboratories Ltd Announces Change to Executive Team as Jitendra N Doshi Assumes Position of CEO 53013 1Caraco Pharmaceutical Laboratories Ltd Announces Change to Executive Team as Jitendra N Doshi Assumes Position of CEO 53013 2Human Genome Sciences Announces Pricing of Public Offering of Common Stock 13237 1Human Genome Sciences Announces Pricing of Public Offering of Common Stock 13237 2Human Genome Sciences Announces Pricing of Public Offering of Common Stock 13237 3